Detection of cancer recurrence from Thai-English electronic medical records using sentence embeddings

• by Ekapob Sangariyavanich, Wanchana Ponthongmak, Nawanan Theera-Ampornpunt, Nat Tangchitnob, Gareth J McKay, Ammarin Thakkinstian

• July 2, 2026

Crucial role of IL-6, IL-8, IL-11 and leptin in tumor microenvironment in a group of patients with GEP-NETs- crosstalk between inflammation and cancer

• by Agata Świętek, Joanna K. Strzelczyk, Dorota Hudy, Zenon P. Czuba, Karolina Snopek-Miśta, Mariusz Kryj, Katarzyna Kuśnierz, Marcin Zeman, Malgorzata Oczko-Wojciechowska, Daria Handkiewicz-Junak, Janusz Strzelczyk

• July 2, 2026

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

• July 1, 2026

• 1 min

Robot-assisted laparoscopic resection of giant pelvic solitary fibrous tumor: a case report with literature review

• by Binbin Wang, Gengchen Huang, Wei Wei, Tie Mao, Zihan Gao, Yutao Ma, Yiming Gu

• July 1, 2026